| Type 2 diabetes | Type 1 diabetes | P-valuea | |
---|---|---|---|---|
N | 24 | 148 | Â | |
Age (years) | 50 (41, 57; 31–59) | 46 (40, 53; 32–59) | 0.38b | |
Gender | Men | 12 (50) | 83 (56) | 0.66 |
Women | 12 (50) | 65 (44) | ||
Diabetes duration (years) | 11 (7, 14; 2–32) | 24 (14, 33; 1–55) | < 0.001b | |
Depression (HADS-D ≥ 8 p) | 6 (25) | 17 (12) | 0.10 | |
Alexithymia (TAS-20 ≥ 61 p) | 6 (25) | 19 (13) | 0.12 | |
Anxiety (HADS-A ≥ 8 p) | 9 (38) | 52 (35) | 0.82 | |
Physical inactivity | 4 (19) | 11 (8) | 0.10 | |
Smoking | 2 (9) | 12 (8) | > 0.99 | |
MSC (nmol/L) All measurements | 7.8 (5.1, 12.0; 1.9–23.0) | 5.2 (3.1, 7.8; 1.9–47.0) | 0.006b | |
MSC (nmol/L) Spring | 6.7 (3.6, 11.5; 1.9–13.0) | 7.1 (5.2, 10.0; 1.9–31.0) | 0.84b | |
MSC (nmol/L) Summer | 7.6 (7.2, 13,5; 6.8–15.0) | 4.8 (3.0, 11.0; 2.3–47.0) | 0.051b | |
MSC (nmol/L) Autumn/early winter | 8.1 (4.5, 16.2; 3.2–23.0) | 3.2 (2.7, 5.4; 1.9–26.0) | 0.001b | |
High MSC (≥ 9.3 nmol/L) | 9 (38) | 33 (22) | 0.13 | |
HbA1c | mmol/mol | 60 (49, 75; 41–113) | 63 (55, 71; 32–110) | 0.78b |
% | 7.6 (6.6, 9.0; 5.9–12.5) | 7.9 (7.2, 8.6; 5.1–12.2) | ||
HbA1c > 70 mmol/mol (> 8.6%) | 8 (33) | 38 (26) | 0.46 | |
BMI (kg/m2) Men | 31 (28, 32; 26–34) | 25 (23, 28; 18–38) | < 0.001b | |
BMI (kg/m2) Women | 31 (24, 36; 21–39) | 24 (23, 27; 18–45) | 0.012b | |
Obesity (BMI ≥ 30 kg/m2) | 14 (58) | 16 (11) | < 0.001 | |
Inhaled steroids | 1 (4) | 13 (7) | 0.70 | |
Antidepressants | 2 (8) | 12 (8) | > 0.99 | |
Clinical psychiatric diagnoses | 4 (17) | 20 (14) | 0.54 | |
Foot complications | 5 (22) | 28 (20) | 0.78 | |
Cardiovascular complications | 4 (17) | 7 (5) | 0.049 | |
Diabetes retinopathy | 14 (58) | 116 (79) | 0.039 |